Abstract 1292
Background
Inhibitor of differentiation 1 (Id1) and 3 (Id3) genes confer poor prognosis being involved in LA spreading to the liver. KM may constitute a poor prognosis and a pro-metastatic feature. Here we study Id genes' role in KM LA and liver metastasis (LM).
Methods
424 LA patients were studied to assess the survival impact of Id1 and Id3 mRNA levels depending on KRAS status. The KM human LA cell line H1792-TGL-604 was used to address the impact of Id1 and Id3 genes on tumor cell proliferation and migration. A murine model of LM from LA was generated using immunocompromised mice by tumor cells intrasplenic injection. shRNA silencing was used to determine the impact of Idgenes. Two groups of mice inoculated with shRNA-Id1 and shRNA-Id1-Id3 tumor cells, were compared to those inoculated with twildtype (WT) cell line. FDG-PET was used to monitor LM. The effect of tumor cells genotype in the overall survival (OS) of the animals was also studied.
Results
Id1 and Id3 mRNA higher tumor levels predicted a shorter OS among patients with KM but not in KRAS-wildtype LA (p = 0.02 and p = 0.03, respectively). In vitro, the proliferation rate of cells silenced for Id1 and Id1/Id3 genes was 20.1% CI95% (0.17, 0.23) and 31% CI95% (0.245, 0.37), compared to 60.1% CI95% (0.54, 0.67), in the WT cell line (p
Conclusions
Higher Id1 and Id3 mRNA tumor levels predicted a shorter OS in a large series of KM LA patients. Id1 and Id1/Id3 silencing in human KM tumor cells of LA decreased and delayed LM development in an in vivo model
Clinical trial identification
Legal entity responsible for the study
Clinica Universidad de Navarra
Funding
Ministerio de Economía y Competitividad. Instituto de Salud Carlos III. Gobierno de España.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract